Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positi… - SLUB Dresden

Media type: E-Article
Title: Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma Kombination von Nivolumab mit Standard-Induktionschemotherapie bei Kindern und Erwachsenen mit EBV-positivem Nasopharynxkarzinom : Protocol of a prospective multicenter phase 2 trial Protokoll einer prospektiven multizentrischen Phase-II-Studie : Protocol of a prospective multicenter phase 2 trial
Contributor: Römer, Tristan; Vokuhl, Christian; Staatz, Gundula; Mottaghy, Felix M.; Christiansen, Hans; Eble, Michael J.; Timmermann, Beate; Klussmann, Jens Peter; Elbracht, Miriam; Calaminus, Gabriele; Zimmermann, Martin; Brümmendorf, Tim H.; Feuchtinger, Tobias; Kerp, Helena; Kontny, Udo
imprint: Springer Science and Business Media LLC, 2024
Published in: HNO
Language: English
DOI: 10.1007/s00106-023-01404-9
ISSN: 0017-6192; 1433-0458
Keywords: Otorhinolaryngology
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Treatment of Epstein-Barr virus(EBV)-positive nasopharyngeal carcinoma (NPC) with cisplatin/5-fluorouracil (5-FU) induction chemotherapy, followed by radiochemotherapy and subsequent interferon‑β, has yielded high survival rates in children, adolescents, and young adults. A previous study has shown that reduction of radiation dose from 59.4 to 54.0 Gy appears to be safe in patients with complete response (CR) to induction chemotherapy. As immune checkpoint-inhibitors have shown activity in NPC, we hypothesize that the addition of nivolumab to standard induction chemotherapy would increase the rate of complete tumor responses, thus allowing for a reduced radiation dose in a greater proportion of patients.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>This is a prospective multicenter phase 2 clinical trial including pediatric and adult patients with their first diagnosis of EBV-positive NPC, scheduled to receive nivolumab in addition to standard induction chemotherapy. In cases of non-response to induction therapy (stable or progressive disease), and in patients with initial distant metastasis, treatment with nivolumab will be continued during radiochemotherapy. Primary endpoint is tumor response on magnetic resonance imaging (MRI) and positron emission tomography (PET) after three cycles of induction chemotherapy. Secondary endpoints are event-free (EFS) and overall survival (OS), safety, and correlation of tumor response with programmed cell death ligand 1 (PD-L1) expression.</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>As cure rates in localized EBV-positive NPC today are high with standard multimodal treatment, the focus increasingly shifts toward prevention of late effects, the burden of which is exceptionally high, mainly due to intense radiotherapy. Furthermore, survival in patients with metastatic disease and resistant to conventional chemotherapy remains poor. Primary objective of this study is to investigate whether the addition of nivolumab to standard induction chemotherapy in children and adults with EBV-positive NPC is able to increase the rate of complete responses, thus enabling a reduction in radiation dose in more patients, but also offer patients with high risk of treatment failure the chance to benefit from the addition of nivolumab.</jats:p> </jats:sec><jats:sec> <jats:title>Trial registration</jats:title> <jats:p>EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) No. 2021-006477-32.</jats:p> </jats:sec>

Search in field:

Recently searched for: